U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 31 - 40 of 12,523 results

Status:
US Approved Rx (2019)
First approved in 2018

Class (Stereo):
CHEMICAL (ACHIRAL)



Brilliant Blue G is triphenylmethane dye that was developed for use in the textile industry but is now commonly used for staining proteins in analytical biochemistry. The Bradford assay is a standard, rapid dye-binding assay that uses Brilliant Blue ...
Status:
US Approved Rx (2017)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) is...
Status:
US Approved Rx (2017)
First approved in 2017

Class (Stereo):
CHEMICAL (ACHIRAL)



Abemaciclib, previously known as LY2835219, is a potent and selective inhibitor of cyclin-dependent kinases: CDK4 and CDK6, developed by Eli Lilly, which is in clinical trial phase III for the treatment of breast cancer and non-small cell lung cancer...
Status:
US Approved Rx (2016)
First approved in 2016

Class (Stereo):
CHEMICAL (ABSOLUTE)



Obeticholic acid (also known as INT-747), is a potent, orally bioavailable farnesoid X receptor (FXR) agonist. The key role of the farnesoid X receptor (FXR) as a regulator of bile and cholesterol metabolism in the liver, with preclinical data from n...
Status:
US Approved Rx (2016)
First approved in 2016

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Brivaracetam (UCB 34714, trade name Briviact), the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years...
Status:
US Approved Rx (2015)
First approved in 2015

Class (Stereo):
CHEMICAL (ACHIRAL)



Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. Alectinib is spe...
Status:
US Approved Rx (2015)
First approved in 2015

Class (Stereo):
CHEMICAL (ACHIRAL)



Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in...
Status:
US Approved Rx (2015)
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)



Eluxadoline, an orally active mixed μ opioid receptor (μOR) agonist δ opioid receptor (δOR) antagonist. Eluxadoline normalizes gastrointestinal (GI) transit and defecation under conditions of novel environment stress or post-inflammatory altered GI f...
Status:
US Approved Rx (2015)
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cariprazine is an antipsychotic approved by FDA for the treatment of schizophrenia and bipolar I disorder. The drug has a unique clinical action which is explained by its ability to act on dopamine D3 receptors. Pharmacology studies revealed that car...
Status:
US Approved Rx (2015)
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cangrelor is a P2Y12 inhibitor that has been approved as an antiplatelet drug. It is marketed in the US under the brand name Kengreal and in Europe as Kengrexal. Cangrelor is an intravenous, direct-acting reversible P2Y12 inhibitor for patients under...